Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlobeImmune
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
(A few general items required)
Patients with non-metastatic pancreas cancer post-resection that have a product-related ras mutation
\>18 years of age
Negative skin test for hypersensitivity to Saccharomyces cerevisiae
You may not be if
Metastatic pancreas cancer patients post-resection
Patients with no product-related ras mutation.
Clareo Health | Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer
